2.31%C 7.40 5.37%QQQQ 27.81 2.83%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
PRINCETON, N.J. - Pharmasset Inc. said Tuesday its hepatitis C treatment candidate met safety goals in part of an early-stage study.
| VRUS | 13.89 |  -0.11 |
The drug candidate, called R7128, was administered to patients over a four-week period in 1,000-milligram doses. The study involved 31 patients.
Safety results were similar to prior sections of the study involving 500-milligram and 1,500-milligram doses. The drug also showed signs of effectiveness, though the study is not designed for that level of testing.
Early-stage, or Phase I clinical trials, are often too small to accurately measure effectiveness and are primarily used to determine dosing levels for later studies and to test for safety. The company expects to have Phase II, or midstage, study results filed with the Food and Drug Administration this fall.
Hepatitis C is an infectious disease that affects a person's liver. It is spread by blood-to-blood contact and symptoms include inflammation and scarring of the liver.
Shares of Pharmasset closed at $22.01 Monday.
U.S. stocks were mixed on Thursday after retailers reported mostly disappointing sales while other big-name companies announced layoffs and Europ...
China markets opened lower on Tuesday morning as the investors' confidence hit by the signals that global recession are deepening.
The markets have spoken: risk aversion is still the name of the game and that was obvious since the beginning of the week.
Building your business and corporate credit for your small business.
Get your next web design project done with our los angeles web design team - Best web design with great price.
Baldwin Linguas:
Translations Interpreting Localization:
English French Portuguese Spanish
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
